Zeprumetostat combinations for relapsed peripheral T-cell lymphoma
Part of Cancer clinical trials.
This study tests a new drug, zeprumetostat, combined with other treatments for people with a type of lymphoma that has come back or not responded to previous therapy. The goal is to see if these combinations can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lymphoma called peripheral T-cell lymphoma (PTCL), specifically the subtypes PTCL-NOS or TFHL.
- Your lymphoma has come back after treatment or did not respond to at least one prior treatment.
- You are able to take care of yourself (ECOG performance status 0-2).
- You have not taken an EZH2 inhibitor before.
- You are not pregnant or breastfeeding and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, zeprumetosta, for people with a type of skin lymphoma (mycosis fungoides or Sézary syndrome) that has come back or not improved after at least one prior treatment. The goal is to see if the drug can help control the disease.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
This trial tests a new combination of targeted drugs (including an EZH2 inhibitor) for people with peripheral T-cell lymphoma (PTCL) that didn't respond to their first treatment. The drugs are chosen based on the genetic mutations in your tumor, aiming to attack the cancer more precisely.
This trial tests a new drug called zeprumetostat (an EZH2 inhibitor) combined with other treatments for people with mature T-cell or NK-cell lymphoma that has come back or not responded to standard therapy. The goal is to see if the combination can help control the lymphoma.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new PTCL-NOS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.